نتائج البحث - "Signe Rosenlund"

المساهمون: Groningen Institute for Organ Transplantation (GIOT), Lifestyle Medicine (LM), Groningen Kidney Center (GKC), Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), Value, Affordability and Sustainability (VALUE), APH - Health Behaviors & Chronic Diseases, General practice, Epidemiology and Data Science, APH - Aging & Later Life, ACS - Diabetes & metabolism

المصدر: Lancet Diabetes & Endocrinology, 8(4), 301-312. ELSEVIER SCIENCE INC
Tofte, N, Lindhardt, M, Adamova, K, Bakker, S J L, Beige, J, Beulens, J W J, Birkenfeld, A L, Currie, G, Dimos, I, Francová, L, Frimodt-Møller, M, Girman, P, Göke, R, Havrdova, T, Heerspink, H J L, Kooy, A, Laverman, G D, Mischak, H, Navis, G, Nijpels, G, Noutsou, M, Ortiz, A, Parvanova, A, Persson, F, Petrie, J R, Ruggenenti, P L, Rutters, F, Rychlík, I, Siwy, J, Spasovski, G, Speeckaert, M, Trillini, M, Zürbig, P, von der Leyen, H, Rossing, P, PRIORITY investigators & Nijpels, MGAAM 2020, ' Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY) : a prospective observational study and embedded randomised placebo-controlled trial ', The Lancet Diabetes and Endocrinology, vol. 8, no. 4, pp. 301-312 . https://doi.org/10.1016/S2213-8587Test(20)30026-7
Ann Transl Med
The Lancet Diabetes and Endocrinology, 8(4), 301-312. Elsevier BV
Lancet Diabet. Endocrinol. 8, 301-312 (2020)

مصطلحات موضوعية: Adult, Male, Proteomics, medicine.medical_specialty, ALBUMINURIA, NEPHROPATHY, Endocrinology, Diabetes and Metabolism, Population, Placebo-controlled study, 030209 endocrinology & metabolism, Spironolactone, DIAGNOSIS, law.invention, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Randomized controlled trial, law, Internal medicine, Internal Medicine, Clinical endpoint, media_common.cataloged_instance, Medicine, Humans, Diabetic Nephropathies, 030212 general & internal medicine, Prospective Studies, European union, Prospective cohort study, education, media_common, Aged, Mineralocorticoid Receptor Antagonists, education.field_of_study, business.industry, MICROALBUMINURIA, Middle Aged, medicine.disease, Editorial Commentary, Early Diagnosis, Treatment Outcome, Diabetes Mellitus, Type 2, Cohort, Disease Progression, Microalbuminuria, Female, business, Glomerular Filtration Rate

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c330f7cf6c46dc4a204c768eaea4bedTest
https://eprints.gla.ac.uk/212534/13/212534.pdfTest

6

Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial

المؤلفون: Signe Rosenlund, Frederik Persson, Tomasz Pielak, Peter Rossing, Jens Faber, Bernt Johan von Scholten, Jesper Eugen-Olsen, Tine W. Hansen

المصدر: Diabetes, Obesity and Metabolism. 19:901-905

مصطلحات موضوعية: Male, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, 030209 endocrinology & metabolism, Type 2 diabetes, 030204 cardiovascular system & hematology, Placebo, Gastroenterology, Receptors, Urokinase Plasminogen Activator, Adrenomedullin, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Copeptin, Double-Blind Method, Risk Factors, Internal medicine, Internal Medicine, medicine, Clinical endpoint, Albuminuria, Humans, Hypoglycemic Agents, Protein Precursors, Aged, Cross-Over Studies, Tumor Necrosis Factor-alpha, business.industry, Liraglutide, Glycopeptides, Middle Aged, medicine.disease, Crossover study, Peptide Fragments, Diabetes Mellitus, Type 2, SuPAR, Cardiovascular Diseases, Female, medicine.symptom, business, Atrial Natriuretic Factor, Biomarkers, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::008e889681487c4be7b979ee7caa59deTest
https://doi.org/10.1111/dom.12884Test

7

The effect of liraglutide on renal function: A randomized clinical trial

المؤلفون: Jens Faber, Tine W. Hansen, Peter Hovind, Peter Rossing, Signe Rosenlund, Bernt Johan von Scholten, Frederik Persson

المصدر: Diabetes, Obesity and Metabolism. 19:239-247

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::0ef78307ee88663ff98ebefc90114913Test
https://doi.org/10.1111/dom.12808Test

8

94 - Oral Semaglutide vs Placebo in Patients With Type 2 Diabetes and Moderate Renal Impairment: PIONEER 5

المؤلفون: Signe Rosenlund, Thozhukat Sathyapalan, Thalia Marie Blicher, Simon Heller, Ofri Mosenzon, Robyn L. Houlden, Richard E. Pratley, Ole Holm Hels, Jan W. Eriksson, Cyrus Desouza

المصدر: Canadian Journal of Diabetes. 43:S35-S36

مصطلحات موضوعية: medicine.medical_specialty, business.industry, Endocrinology, Diabetes and Metabolism, Semaglutide, General Medicine, Type 2 diabetes, medicine.disease, Placebo, Endocrinology, Internal medicine, Internal Medicine, medicine, In patient, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::fd654afa5c8d1eacfff379f4d71b1e1bTest
https://doi.org/10.1016/j.jcjd.2019.07.103Test

9

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5):a placebo-controlled, randomised, phase 3a trial

المؤلفون: Robert Silver, G Bedel, M Yanovskaya, Simon Heller, T Hart, A Golovach, G Cornett, A Luts, A Chang, L Lewy-Alterbaum, H Nguyen, S Hasan, Amir Tirosh, W Biggs, R Pratley, K Blaze, Ole Holm Hels, A Peskov, P Houser, E Klein, Peter Rossing, H Knoble, T Milovanova, P O'Donnell, S Folkerth, H A Frandsen, S Chandran, A Krzeminski, Richard E. Pratley, J Reed, S Sulosaari, Torben Hansen, T Donner, Jan W. Eriksson, R Jackson, N Krasnopeeva, J Pouzar, E Kazakova, J Gumprecht, Thalia Marie Blicher, E Morawski, S Nieminen, Y Shlesinger, J Parker, Klaus Levin, T Maxwell, Z Shaikh, A Nikkola, E Zhdanova, D Nabriski, T Lysenko, P Norwood, G Vagapova, K Khan, J Eriksson, M Hellgren, Ofri Mosenzon, John Strand, M Hewitt, Naim Shehadeh, B Barker, E Haddad, K Eliasson, Y Pergaeva, T Sathyapalan, M Kunitsyna, Thozhukat Sathyapalan, W Gandy, J Soufer, S Chilka, J Lawhead, P Nicol, M Benson, A Odugbesan, S Aronoff, G Gatipon, R Abramof, L Gonzalez-Orozco, C Desouza, O Mosenzon, I Beshay, H Traylor, B Snyder, Robert S. Lindsay, A Cleland, K Metsärinne, Paweł Bogdański, K Forshaw, M Sergeeva-Kondrachenko, Cyrus Desouza, M Hitz, S Plevin, K Astamirova, N Uhlenius, R Huntley, D Alpenidze, B Delgado, L Zarutskaya, Signe Rosenlund, John A. McKnight, P Levin, E Frolova, S Heller, P E Jakobsen, A Kapoor, R Busch, S Chaidarun, L Connery, S Hietaniemi, Sten Madsbad, M. Shamkhalova, S Lindmark, B Hella, L Belousova, C Mbogua, L Kargina

المصدر: Mosenzon, O, Blicher, T M, Rosenlund, S, Eriksson, J W, Heller, S, Hels, O H, Pratley, R, Sathyapalan, T, Desouza, C, PIONEER 5 Investigators, Abramof, R, Alpenidze, D, Aronoff, S, Astamirova, K, Barker, B, Bedel, G, Belousova, L, Benson, M, Beshay, I, Biggs, W, Blaze, K, Bogdanski, P, Busch, R, Chaidarun, S, Chandran, S, Chang, A, Chilka, S, Cleland, A, Connery, L, Cornett, G, Delgado, B, Desouza, C, Donner, T, Eliasson, K, Eriksson, J, Folkerth, S, Forshaw, K, Frandsen, H A, Frolova, E, Gandy, W, Gatipon, G, Golovach, A, Hansen, T K, Hitz, M, Jakobsen, P E, Levin, K, Madsbad, S, Nguyen, H, Parker, J, Reed, J, Rossing, P, Yanovskaya, M, Zarutskaya, L & Zhdanova, E 2019, ' Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5) : a placebo-controlled, randomised, phase 3a trial ', The Lancet Diabetes and Endocrinology, vol. 7, no. 7, pp. 515-527 . https://doi.org/10.1016/S2213-8587Test(19)30192-5
Mosenzon, O, Blicher, T M, Rosenlund, S, Eriksson, J W, Heller, S, Hels, O H, Pratley, R, Sathyapalan, T, Desouza, C & PIONEER 5 Investigators 2019, ' Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5) : a placebo-controlled, randomised, phase 3a trial ', The Lancet Diabetes & Endocrinology, vol. 7, no. 7, pp. 515-527 . https://doi.org/10.1016/S2213-8587Test(19)30192-5

مصطلحات موضوعية: Male, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Population, Glucagon-Like Peptides, Administration, Oral, 030209 endocrinology & metabolism, Type 2 diabetes, Placebo, Glucagon-Like Peptide-1 Receptor, law.invention, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Double-Blind Method, Randomized controlled trial, law, Internal medicine, Internal Medicine, medicine, Clinical endpoint, Humans, Diabetic Nephropathies, Renal Insufficiency, 030212 general & internal medicine, education, Aged, education.field_of_study, business.industry, Semaglutide, Middle Aged, medicine.disease, Discontinuation, Clinical trial, Treatment Outcome, Diabetes Mellitus, Type 2, Female, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d569511b15de88f728dd8364203edd9Test
https://curis.ku.dk/ws/files/251035512/Efficacy_and_safety_of_oral_semaglutide_in_patients_with_type_2_diabetes_and_moderate_renal_impairment_PIONEER_5_accepted_version_.pdfTest

10

1004-P: Oral Semaglutide vs. Placebo in Patients with Type 2 Diabetes and Moderate Renal Impairment: PIONEER 5

المؤلفون: Signe Rosenlund, Simon Heller, Thozhukat Sathyapalan, Richard E. Pratley, Ole H. Hels, Thalia Marie Blicher, Ofri Mosenzon, Cyrus Desouza, Jan W. Eriksson

المصدر: Diabetes. 68

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::474220cee00fc5cdb4e8fc94fa609875Test
https://doi.org/10.2337/db19-1004-pTest

تنقيح النتائج